Remogliflozin etabonate is an orally available, novel, potent inhibitor of SGLT2, and has been shown in numerous clinical trials to be a safe and efficacious monotherapy for the treatment of T2DM [12, 19–21]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.